Director of Clinical Research & Richard Saltonstall Chair in Oncology, MGH Cancer Center
Professor of Medicine, Harvard Medical School
Oncogene targeted therapy, cancer immunotherapy, early drug development
EDUCATION
BS – Yale University
MD – Johns Hopkins University
Residency – Brigham & Women’s Hospital (Harvard Medical School)
Postdoctoral Fellow – University of Pennsylvania
AWARDS AND ACCOLADES
NCI Cancer Therapeutics Evaluation Program Michaele Christian Oncology Development Award and Lectureship, 2015
NCI Board of Scientific Advisors, 2018 | Chair as of 2021
AACR Board of Directors, 2018
Society for Melanoma Research Lifetime Achievement Award, 2019
OncLive Giants of Cancer Care, 2020
COMPANIES AND BOARDS
Co-Founder: Loxo Oncology (acquired by Lily), Strata Oncology, X4 Pharmaceuticals, Apricity, C-Reveal, and Scorpion Therapeutics
Board of Directors: Loxo Oncology, Scorpion Therapeutics, Strata Oncology, Checkmate Pharmaceuticals (acquired 2022), Clovis Oncology, Kinnate Biopharma
Scientific Advisory Board: PIC Therapeutics, Apricity, Tvardi, ALX Oncology, xCures, Monopteros, Vibliome, Soley Therapeutics, Quanta Therapeutics, and intrECate